Anthony Giannetti, PhD, associate director, applications, Carterra, got his start in biophysics and structural biology while earning his B.S. in chemistry at the University of California at Santa Barbara. He earned his Ph.D. in Biochemistry and Molecular Biophysics at the California Institute of Technology before joining Roche, Palo Alto, in 2005.  Since then, he has worked at Genentech, Google[X] and their spin-out Verily, and contributed novel biophysical approaches in clinical pharmacology leading to the approval of Erivdge (visomodegib), the first treatment for metastatic basal-cell carcinoma. He brings to Carterra over 20 years of experience in the use of biophysical approaches to drug discovery.